DeepMed Research

ISTITUTO ONCOLOGICO VENETO

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.ioveneto.it

Clinical Trials

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Regorafenib 40 MG Oral Tablet [STIVARGA]

First Posted Date: 2021-03-22

Last Posted Date: 2024-02-08

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 192

Registration Number: NCT04810182

Locations: 🇮🇹
Policlinico Universitario di Bari, Bari, BA, Italy
🇮🇹
IRCCS "Saverio de Bellis", Castellana Grotte, BA, Italy
🇮🇹
Ospedlae S. Martino, Belluno, BL, Italy

and more 26 locations

Conservative Management of CIN2 Lesions and Biomarkers Evaluation

Completed

Conditions: CIN2

First Posted Date: 2020-12-29

Last Posted Date: 2023-09-28

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 319

Registration Number: NCT04687267

Locations: 🇮🇹
Azienda ULSS 6 Euganea, Padova, PD, Italy
🇮🇹
Azienda ULSS 2 Marca Trevigiana, Treviso, TV, Italy
🇮🇹
Azienda ULSS 9 Scaligera, Verona, VR, Italy

and more 1 locations

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Triptorelin
Drug: Exemestane
Drug: Nivolumab

First Posted Date: 2020-12-09

Last Posted Date: 2020-12-09

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 43

Registration Number: NCT04659551

Locations: 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹
Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹
Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy

and more 2 locations

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Phase 3

Terminated

Conditions: Soft Tissue Sarcoma Adult

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2020-12-07

Last Posted Date: 2024-07-08

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 79

Registration Number: NCT04656262

Locations: 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy
🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy
🇮🇹
Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy

and more 10 locations

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Active, not recruiting

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-06-04

Last Posted Date: 2024-02-21

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 100

Registration Number: NCT04416646

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy

CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO).

Not Applicable

Completed

Conditions: Overweight and Obesity
Barrett's Esophagus

Interventions: Behavioral: Calorie and protein restriction diet

First Posted Date: 2019-01-23

Last Posted Date: 2023-10-16

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 160

Registration Number: NCT03813381

Immunophenotyping of Metastases From Colorectal Cancer

Completed

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2018-07-30

Last Posted Date: 2020-11-20

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 10

Registration Number: NCT03604926

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer

Active, not recruiting

Conditions: Elderly Metastatic Colorectal Cancer Patients

First Posted Date: 2018-03-01

Last Posted Date: 2023-11-29

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 121

Registration Number: NCT03451370

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padua, Italy

The GOLD Study: G8 in OLDer Patients

Active, not recruiting

Conditions: Elderly Metastatic Colorectal Cancer Patients

First Posted Date: 2018-02-28

Last Posted Date: 2023-11-29

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 109

Registration Number: NCT03449914

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padua, Italy

Regorafenib in Relapsed Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Lomustine
Drug: Regorafenib

First Posted Date: 2016-10-06

Last Posted Date: 2022-09-09

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 119

Registration Number: NCT02926222

Locations: 🇮🇹
IRCCS "Saverio de Bellis, Castellana Grotte, BA, Italy
🇮🇹
Azienda Ospedaliera "G.Rummo", Benevento, BR, Italy
🇮🇹
istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy